Figure 2.
MYCN drives PTCL in a bone marrow transplant model. (A) Schematic overview of the bone marrow transplant assay strategy used to restrict MYCN expression to the lymphoid lineage. (B) Kaplan-Meier overall survival curve for mice transplanted with CD2 Cre HSPCs transduced with empty vector (EV) (n = 5) or the LoxP MYCN retroviral vector (n = 22). (C) Kaplan-Meier overall survival curve for secondary transplants of MYCN-driven B-cell lymphoma (n = 5) or MYCN-driven T-cell lymphoma (n = 18). (D) Kaplan-Meier overall survival curve for mice transplanted with CD4 Cre HSPCs transduced with the LoxP MYCN retroviral vector (n = 5) and secondary transplants from the resulting T-cell lymphomas (n = 5). (E) Spleen and thymus weights in mice that develop MYCN-driven B-cell lymphomas (BCL) or TCL or wild-type (WT) mice. (F) Infiltration of GFP-positive cells in different organs from mice that develop MYCN-driven TCL. LN, lymph node; BM, bone marrow; PB, peripheral blood. (G) White blood cell counts of WT mice or recipient mice transplanted with CD2 Cre cells transduced with the LoxP MYCN retroviral vector at end-stage disease (TCL). (H) Representative fluorescence-activated cell sorter (FACS) analysis showing CD3e expression in GFP-positive spleen cells of mice that developed MYCN-driven TCL (left and middle). The mean fluorescence intensity is shown on the right. SSC, side scatter. (I) Representative FACS analysis showing CD4 expression in GFP-positive spleen cells of mice that developed MYCN-driven TCL (left). The mean fluorescence intensity is shown on the right. (J) Hematoxylin and eosin stainings on a spleen from a mouse transplanted with HSPCs expressing EV (GFP) and a spleen from the murine MYCN-driven TCL. Scale bars indicate 200 μm (black) or 20 μm (white). (K) Immunofluorescent staining showing GFP or Cd3e in a spleen from a mouse transplanted with HSPCs expressing EV and a spleen from a mouse that developed MYCN-driven TCL. Scale bars indicate 200 μm. See also supplemental Figure 2. DAPI, 4′,6-diamidino-2-phenylindole.

MYCN drives PTCL in a bone marrow transplant model. (A) Schematic overview of the bone marrow transplant assay strategy used to restrict MYCN expression to the lymphoid lineage. (B) Kaplan-Meier overall survival curve for mice transplanted with CD2 Cre HSPCs transduced with empty vector (EV) (n = 5) or the LoxP MYCN retroviral vector (n = 22). (C) Kaplan-Meier overall survival curve for secondary transplants of MYCN-driven B-cell lymphoma (n = 5) or MYCN-driven T-cell lymphoma (n = 18). (D) Kaplan-Meier overall survival curve for mice transplanted with CD4 Cre HSPCs transduced with the LoxP MYCN retroviral vector (n = 5) and secondary transplants from the resulting T-cell lymphomas (n = 5). (E) Spleen and thymus weights in mice that develop MYCN-driven B-cell lymphomas (BCL) or TCL or wild-type (WT) mice. (F) Infiltration of GFP-positive cells in different organs from mice that develop MYCN-driven TCL. LN, lymph node; BM, bone marrow; PB, peripheral blood. (G) White blood cell counts of WT mice or recipient mice transplanted with CD2 Cre cells transduced with the LoxP MYCN retroviral vector at end-stage disease (TCL). (H) Representative fluorescence-activated cell sorter (FACS) analysis showing CD3e expression in GFP-positive spleen cells of mice that developed MYCN-driven TCL (left and middle). The mean fluorescence intensity is shown on the right. SSC, side scatter. (I) Representative FACS analysis showing CD4 expression in GFP-positive spleen cells of mice that developed MYCN-driven TCL (left). The mean fluorescence intensity is shown on the right. (J) Hematoxylin and eosin stainings on a spleen from a mouse transplanted with HSPCs expressing EV (GFP) and a spleen from the murine MYCN-driven TCL. Scale bars indicate 200 μm (black) or 20 μm (white). (K) Immunofluorescent staining showing GFP or Cd3e in a spleen from a mouse transplanted with HSPCs expressing EV and a spleen from a mouse that developed MYCN-driven TCL. Scale bars indicate 200 μm. See also supplemental Figure 2. DAPI, 4′,6-diamidino-2-phenylindole.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal